key: cord-0981679-s4geovzo
authors: Jin, Xinyao; Chua, Hui Zi; Wang, Keyi; Li, Nan; Zheng, Wenke; Pang, Wentai; Yang, Fengwen; Pang, Bo; Zhang, Mingyan; Zhang, Junhua
title: Evidence for the medicinal value of Squama Manitis (pangolin scale): a systematic review
date: 2020-07-28
journal: Integr Med Res
DOI: 10.1016/j.imr.2020.100486
sha: c9c79ac3a213307b00df260224e9978337ecfabc
doc_id: 981679
cord_uid: s4geovzo

BACKGROUND: Squama Manitis (pangolin scale) has been used in traditional Chinese medicine for thousands of years. However, its efficacy has not been systematically reviewed. This review aims to fill the gat. METHODS: We searched six electronic databases including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure Database (CNKI), WanFang Database and SinoMed from inception to May 1, 2020. Search terms included “pangolin”, “Squama Manitis”, “Manis crassicaudata”, “Manis javanica”, “Malayan pangolins”, “Manis pentadactyla”, “Ling Li”, “Chuan Shan Jia”, “Shan Jia”, “Pao Jia Zhu”, “Jia Pian” and “Pao Shan Jia”. The Cochrane Risk of Bias (RoB) assessment tool and Newcastle-Ottawa Scale (NOS) were used to evaluate the risk of bias of the included randomized controlled trials (RCTs) and case control studies (CCSs). RESULTS: After screening, 15 articles that met the inclusion criteria were finally included. There were 4 randomized controlled trials, 1 case control study, 3 case series and 7 case reports. A total of 15 different diseases were reported in these studies, thus the data could not be merged and descriptive analysis was carried out. Included RCTs of this review have shown that Squama Manitis combined with herbal decoction was superior to herbal decoction alone in the treatment of postpartum hypogalactia (RR 1.21, 95% CI1.11 to 1.32, P < 0.00001) and breast hyperplasia (RR 1.07, 95% CI 0.96 to 1.19, P = 0.24), and the clinical efficacy of Squama Manitis combined with antibiotics was better than antibiotics alone for acute mastitis (RR 1.13, 95% CI 0.95 to 1.35, P = 0.16) and mesenteric lymphadenitis (RR 1.51, 95% CI 1.09 to 2.09, P = 0.01). The methodological quality was generally low in all included reports. CONCLUSION: There is no reliable evidence that Squama Manitis has special medicinal value. The removal of Squama Manitis from Pharmacopoeia is rational.

Coronavirus Disease 2019 , caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has evolved into a global pandemic. [1] Its origin remains unclear.

Several studies suggested that bats might be the natural host for SARS-CoV-2, [2] [3] while snakes and pangolin were potential intermediate hosts of SARS-CoV-2 transmission to humans. Various types of virus host in wild animals can threaten human health and safety. The Squama Manitis (pangolin scale) is a medicinal material in traditional Chinese medicine (TCM), commonly used in promoting lactation in women and reduce swelling. [9] Due to the exaggeration of its medicinal value, pangolins were facing extinction caused by excessive killing. [10] In 2019, pangolin has been listed in International Union for Conservation of Nature (IUCN) Red List of threatened species. In order to enhance the protection of pangolin, China officially proclaimed pangolin to be a national level protected wildlife animal on June 3, 2020. [11] In Chinese Pharmacopoeia(2020 edition), Squama Manitis has been removed. 

We developed a comprehensive literature search by electronic literature databases including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure Database (CNKI), WanFang Database and SinoMed from inception to May 1, 2020. "Pangolin", "Squama Manitis", "Manis crassicaudata", "Manis javanica", "Malayan pangolins", "Manis pentadactyla", "Ling Li", "Chuan Shan Jia", "Shan Jia", "Pao Jia Zhu", "Jia Pian" and "Pao Shan Jia" were used as key words in different databases. The search strategy in PubMed is presented in supplement 1 and the search strategy in CNKI is presented in supplement 2.

We included all types of clinical studies in this review, consisting of randomized controlled trials (RCTs), case control studies (CCSs), case series and case reports. No restrictions were applied on age, gender or ethnicity. For controlled studies, trials that applied Squama Manitis at any dosage for the intervention groups were included, either alone or in combination with herbal or western medicine.

Combinations used for both intervention and control groups were the same. As for case series and case reports, we only included which applied Squama Manitis alone. There were no restrictions on the outcomes of included studies.

Two reviewers (KW, NL) screened all included studies by their titles and abstracts according to the inclusion criteria. Any disagreement in the study selection was resolved by a third reviewer (WZ).

Eligible studies were reviewed by two researchers (KW, NL) independently and data was extracted and cross-checked. Data was extracted using a pre-designed excel sheet: authors, years of publication, J o u r n a l P r e -p r o o f interventions, diseases and outcomes. Any disagreement in the suitability of a study for inclusion in this review was discussed or consulted with a third researcher (WZ).

The qualities of RCTs were assessed by Cochrane Risk of Bias (RoB) assessment tool, [12] which included six aspects: (1) Random sequence generation, (2) Allocation concealment, (3) Blinding of patients and personnel, (4) Incomplete outcome data, (5) Selective reporting, (6) Other bias. The assessment results were presented as "low risk", "high risk" and "unclear risk". The qualities of CCSs were assessed by Newcastle-Ottawa Scale (NOS). [13] The NOS contained three components with eight questions: (1) selection of the groups of the study, (2) comparability, (3) assessment of the outcome. A scoring system of 9 points is used to assess the quality of CCSs，with higher score equating for better quality. Two researchers carried out the quality assessment independently. Disagreement was resolved after consensus or consulting a third researcher.

Review Manager (RevMan) version 5.3 software was used to perform statistical analysis. Risk ratio (RR) with a 95% confidence interval (CI) was adopted for dichotomous outcomes. Mean difference (MD) with a 95% CI was used for continuous outcomes. Cochrane's Q and I 2 were used to explore the heterogeneity. Due to different diseases, interventions and outcomes reported in the included studies, we were not able to perform any estimate of pooled effect.

A total of 4640 records were identified as potentially eligible for inclusion. After excluding duplicates, 3026 studies were screened by their titles and abstracts. According to the inclusion criteria, 151 articles were preliminarily selected for further assessment and 136 of them were excluded because of review articles, animal experiments, pharmaceutical research and theory analysis. Finally, 15 articles were included for analyses (Fig. 1 ).

Types of the 15 included studies [14-1516171819202122-2324252627] were 4 RCTs, [14] [15] [16] [17] 1 CCS, [18] 3 case series [19] [20] [21] and7 case reports. [22] [23] [24] [25] [26] [27] [28] These studies were published from 1989 to 2018, with eighty percent of them published 10 years ago. Fifteen research articles covered 15 types of diseases, which include chronic leg ulcers, verruca plana, neurodermatitis, paronychia, periarteritis nodosa, periarthritis of shoulder, mesenteric lymphadenitis, tremor paralysis, glomerulonephritis, hyperlipidemia, leucopenia after chemotherapy, postpartum hypogalactia, breast hyperplasia and mastitis. Details of RCTs and non-RCTs were shown in Table 1 and Table 2 respectively.

The risk of bias assessment on each included RCT was presented in Fig. 2 and Fig 3. Among the 4 included RCTs, two of them were assessed with a high risk of selection bias based on their incorrect utilization of randomization methods and the studies did not have a clear reporting of random sequence generation. [14] [15] Two other RCTs have unclear random sequence generation. One RCT of Squama Manitis in the treatment of postpartum hypogalactia was assessed with a high risk of selection bias due to its incorrect usage of allocation concealment methods [14] and the remaining RCTs have unclear allocation concealment. There was also lack of reporting for blinding of participants and personnel and J o u r n a l P r e -p r o o f blinding of outcomes assessment, resulting in an unclear assessment for performance and detection bias. High attrition bias was assessed for an RCT using Squama Manitis in the treatment of mesenteric lymphadenitis in children, with a loss in follow up of 4 patients in the control group. [17] The remaining RCTs were assessed with a low risk of attribution bias. Reporting bias for all included RCTs was assessed unclear due to the lack of reporting of the study protocol.

One CCS's quality was assessed by NOS [18] , though the study reported the selection of controls (both groups of patients were from the same hospital and the same department), but there was a lack of clarity for the rest of the items of NOS, hence the study was scored as 1 point.

The results of the 4 RCTs were described as follows. Liang et al tested the efficacy rate of Squama Manitis for treating postpartum hypogalactia. [14] They randomly allocated 243 patients treated with either Squama Manitis powder combined with herbal decoction (n=123) or herbal decoction alone (n=120). The results showed that Squama Manitis powder combined with herbal decoction has a higher efficacy rate than using herbal decoction alone (RR 1.21, 95% CI 1.11 to 1.32, P＜0.00001).

Jiang et al tested the efficacy rate of Squama Manitis for treating breast hyperplasia. [ The CCS had 13 patients in Squama Manitis group and 40 patients in control group. [18] Number of leukocytes in both groups before and after treatment were reported. The total number of leukocytes in the treatment group was maintained at about 6×10 9 /L, and that in the control group was maintained at (4-5)×10 9 /L. There were 3 case series [19] [20] [21] in treating prostatic hyperplasia, paronychia, hyperlipidemia，with sample size of 42, 100 and 62 respectively. The results showed that the Squama Manitis powder treat prostatic Hyperplasia had the efficacy rate of 95%. [19] Squama Manitis powder(Topical)combined with conventional disinfection had 100% efficacy rate of treating paronychia. [20] Squama Manitis powder treating hyperlipidemia had 74% efficacy rate of lowering cholesterol and had 65.5% efficacy rate of lowering triglyceride. [21] There were 7 case reports, [14] [15] [16] [17] [18] [19] [20] which covered disease of chronic leg ulcer, periarteritis nodosa, verruca plana, neurodermatitis, parkinsonian disorders, glomerulonephritis and periarthritis of the shoulder. The results of these case reports showed that Squama Manitis had better effect on the above diseases. Since there is no control in the above studies of case reports and case series, the efficacy of Squama Manitis was not scientifically tested.

All the diseases above have conventional effective treatments. It is deemed unnecessary to use J o u r n a l P r e -p r o o f Squama Manitis in treating the above common diseases due to the lack of evidence for clinical efficacy.

Study type Sample Size(T/C)

Intervention Control Course of treatment Liang (2018) [14] RCTs 243 (123/120) Efficacy rat lowering ch lowering tri Qian (1989) [22] Case report 5 Chronic leg ulcer Squama Manitis powder (topical)

The ulcer h Li (1991) [13] Case report 1 Periarteritis nodosa Squama Manitis powder none 31 days 5 years

Swelling an disappeared Wu (1999) [24] Case report The itching 1 month. Jin (2002) [26] Case report 1 Parkinsonian Disorders Squama Manitis powder none 90 days 3 years After 3 mon stopped, an up. Tian(2002) [27] Case report J o u r n a l P r e -p r o o f Ren (2005) [28] Case report Wild pangolins may carry pathogens that can cause infections in human beings. [6] Hence, it is highly recommended to restrict the use of Squama Manitis as medicine or food in order to protect endangered wildlife species and human safety. [32] In the recent edition of the Chinese Pharmacopoeia, Squama Manitis has been removed from the list. Thus, it is no longer meaningful to conduct RCTs to ascertain the clinical efficacy of Squama Manitis. contents through thin layer, column and spectrum chromatography analysis. In conclusion, there is no reliable evidence for the clinical value of Squama Manitis. It is rational to prohibit the use of Squama Manitis for treatment or healthcare purpose. 

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

A Novel Coronavirus from Patients with Pneumonia in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Cross-species transmission of the newly identified coronavirus 2019-nCoV

Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2

Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (Manitis javanica)

Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID

Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins

Pharmacopoeia of the People's Republic of China

An Overview of Wild Pangolins Status and the Related lllicit Trade in China

The pangolin is promoted to the national first-level protected wildlife

Cochrane Handbook for Systematic Review of Interventions

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses

The effect of Squama Manitis free decoction granules on Low postpartum milk

The effects of different doses of Squam Manitis and different oral hyperplasia of the breast

The clinical efficacy of Squam Manitis powder combined with antibiotics in the treatment of acute mastitis

The clinical effect of Squam Manitis powder on mesenteric lymphadenitis in children

An observational study on Squama Manitis treatment of leukopenia

The Squama Manitis is used to treat 42 patients with Prostatic Hyperplasia

100 cases of paronychia were treated with topical Squama Manitis

Squama Manitis is used to treat chest paralysis and hyperlipidemia

Topical application of Squama Manitis powder to treat leg ulcers

Squama Manitis treatment for Periarteritis Nodosa

Squama Manitis powder for treating verruca plana

Squama Manitis treatment of neurodermatitis

Squama Manitis powder is taken orally for Parkinson's disease

Squama Manitis treat hematuria

Squama Manitis has good effect in the treatment of periarthritis of the Shoulder

One case of allergy caused by oral Squam Manitis

One case of allergic reaction caused by taking Squam Manitis

A case of rash caused by Squam Manitis

Baby pangolins on my plate: possible lessons to learn from the COVID-19 pandemic

Comparative analysis of amino acid content between Squam Manitis and pig toenails

Analysis and comparison of chemical elements and amino acids in pig toenails and Squam Manitis

Substitutes for endangered medicinal animal horns and shells exposed by antithrombotic and anticoagulation effects

Study on the ingredients of Squam Manitis and pig toenails

A comparative study on the chemical composition of Squam Manitis and pig toenails

A Comparative Experiment on the Thin Layer Analysis of Pig Nail and Pangolin

The authors declared that there was no conflict of interest regarding the publication of this paper.J o u r n a l P r e -p r o o f